HUTCHMED (NASDAQ:HCM) Shares Gap Down – Time to Sell?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $10.83, but opened at $10.39. HUTCHMED shares last traded at $10.3790, with a volume of 1,551 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on HCM shares. Bank of America lowered their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Wall Street Zen downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Finally, Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, HUTCHMED presently has a consensus rating of “Hold” and a consensus target price of $16.80.

HUTCHMED Stock Down 2.2%

The company’s 50-day moving average price is $12.92 and its 200-day moving average price is $13.88. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC lifted its stake in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the last quarter. UBS Group AG lifted its stake in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after acquiring an additional 72,614 shares during the last quarter. Amundi lifted its stake in HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after acquiring an additional 65,898 shares during the last quarter. M&G PLC lifted its stake in HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after acquiring an additional 54,601 shares during the last quarter. Finally, XY Capital Ltd lifted its stake in HUTCHMED by 291.1% in the third quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock valued at $831,000 after acquiring an additional 39,266 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.